Marché de la maladie cœliaque en Amérique du Nord et en Europe – Tendances et prévisions du secteur jusqu’en 2031

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché de la maladie cœliaque en Amérique du Nord et en Europe – Tendances et prévisions du secteur jusqu’en 2031

  • Pharmaceutical
  • Publish Reports
  • Dec 2023
  • Country Level
  • 350 Pages
  • Nombre de tableaux : 380
  • Nombre de figures : 95

North America And Europe Celiac Disease Market

Taille du marché en milliards USD

TCAC :  % Diagram

Diagram Période de prévision
2024 –2031
Diagram Taille du marché (année de référence)
USD 94,325.34 Thousand
Diagram Taille du marché (année de prévision)
USD 193,364.33 Thousand
Diagram TCAC
%
DiagramPrincipaux acteurs du marché
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5 < /li>

Marché de la maladie cœliaque en Amérique du Nord et en Europe, par type de traitement (corticostéroïdes, immunosuppresseurs et autres), type de maladie (maladie cœliaque classique, maladie cœliaque non classique, maladie cœliaque réfractaire, maladie cœliaque potentielle et dermatite herpétiforme), type de médicament (génériques et de marque), type d’ordonnance (sur ordonnance et en vente libre), forme posologique (comprimé, gélules, injection et autre), voie d’administration (orale, intraveineuse et topique), type de population (enfants, adultes et gériatrique), utilisateur final (hôpitaux, cliniques, centres de diagnostic, milieux de soins à domicile et autres), canal de distribution (pharmacie hospitalière, pharmacie de détail, pharmacie en ligne et autres) – Tendances et prévisions de l’industrie jusqu’en 2031.

Analyse et perspectives du marché de la maladie cœliaque en Amérique du Nord et en Europe

La dynamique du marché de la maladie cœliaque en Amérique du Nord et en Europe est influencée par des facteurs tels que la prévalence croissante de la maladie, les progrès des technologies de diagnostic et l’expansion du marché des produits sans gluten. Les prestataires de soins de santé de ces régions jouent un rôle crucial dans la sensibilisation, la réalisation de dépistages et la mise en œuvre de stratégies de traitement. En outre, l’intérêt croissant pour les régimes sans gluten en tant que choix de vie au sein de la population générale contribue à l’expansion du marché.

Marché de la maladie cœliaque en Amérique du Nord et en EuropeMarché de la maladie cœliaque en Amérique du Nord et en Europe

Dans l’ensemble, le marché de la maladie cœliaque en Amérique du Nord et en Europe reflète une interaction dynamique entre les initiatives de sensibilisation, de diagnostic et de recherche visant à améliorer la vie des personnes touchées par cette maladie auto-immune. Cependant, le marché est confronté à des défis tels que la complexité de la maladie et les effets secondaires associés aux médicaments utilisés pour le traitement de la maladie cœliaque.

Le marché nord-américain de la maladie cœliaque devrait connaître une croissance de marché au cours de la période de prévision de 2024 à 2031. Data Bridge Market Research analyse que le marché croît avec un TCAC de 9,8 % au cours de la période de prévision de 2024 à 2031 et devrait atteindre 193 364,33 milliers USD d'ici 2031 contre 94 325,34 milliers USD en 2023.

Le marché européen de la maladie cœliaque devrait connaître une croissance de marché au cours de la période de prévision de 2024 à 2031. Data Bridge Market Research analyse que le marché croît avec un TCAC de 8,8 % au cours de la période de prévision de 2024 à 2031 et devrait atteindre 150 949,09 milliers USD d'ici 2031 contre 78 786,35 milliers USD en 2023.

Rapport métrique

Détails

Période de prévision

2024 à 2031

Année de base

2023

Années historiques

2022 (personnalisable pour 2020-2021)

Unités quantitatives

Chiffre d'affaires en milliers de dollars américains, volumes en unités

Segments couverts

Treatment Type (Corticosteriods, Immunosuppressants and Others), Disease Type (Classical Celiac Disease, Non-Classical Celiac Disease, Refractory Celiac Disease, Potential Celiac Disease and Dermatitis Herpetiformis), Drug Type (Generics and Branded), Prescription Type (Prescription and Over The Counter), Dosage Form (Tablet, Capsules, Injection and Other), Route of Administration (Oral, Intravenous and Topical), Population Type (Children, Adults and Geriatric), End User (Hospitals, Clinics, Diagnostic Centres, Home Care Settings and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others)

Countries Covered

U.S., Canada, Mexico, Germany, France, Italy, Spain, U.K., Switzerland, Netherlands, Russia, Turkey, Poland, Sweden, Belgium, Denmark, Finland, Norway and Rest of Europe

Market Players Covered

Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals (subsidiary of Bausch Health Companies Inc.), Tillotts Pharma AG, GSK plc., ImmunogenX, Inc., Janssen Pharmaceuticals, Inc. (subsidiary of Johnson & Johnson Services, Inc.), Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., AstraZeneca, Novartis AG, AdvaCare Pharma, ANOKION, Topas Therapeutics,  Immunic Therapeutics and Equillium Bio. among others

Market Definition

Celiac disease, is a chronic autoimmune disorder characterized by an abnormal immune response to the ingestion of gluten—a protein found in wheat, barley, and rye. When individuals with celiac disease consume gluten, their immune system mistakenly attacks the lining of the small intestine, leading to inflammation and damage to the villi, finger-like projections responsible for nutrient absorption. This immune reaction results in a range of gastrointestinal and systemic symptoms, including abdominal pain, diarrhea, weight loss, fatigue, and nutritional deficiencies.

The diagnosis of celiac disease often involves a combination of blood tests to detect specific antibodies and confirmatory intestinal biopsy. The primary and lifelong treatment for celiac disease is a strict gluten-free diet. By eliminating gluten from their diet, individuals with celiac disease can manage symptoms, promote intestinal healing, and prevent complications. Adherence to a gluten-free lifestyle is crucial, as even small amounts of gluten can trigger immune responses and exacerbate the condition. Celiac disease can affect people of all ages, and while it is a lifelong condition, with proper management, individuals can lead healthy and fulfilling lives.

North America and Europe Celiac Disease Market Dynamics

Drivers

  • Increasing Prevalence Of Celiac Disease

Celiac disease is an autoimmune disorder characterized by an intolerance to gluten, a protein found in wheat, barley, and rye. The prevalence of celiac disease has been on the rise in recent years, and several factors contribute to this increase.

In North America and Europe, where the westernized diet is prevalent, the shift towards increased gluten consumption further amplifies the market's growth. Thus increasing prevalence of celiac disease is expected to act as driver for the North America and Europe celiac disease market.

  • Rising Demand For Gluten Containing Products

Gluten-containing products are made from ingredients that naturally contain gluten. This includes wheat-based products such as bread, pasta, pastries, and cereals. Barley and rye-based products also contain gluten.

In baking, gluten contributes to the rise and texture of bread and other baked goods. These ingredients are used in a variety of food items, from baked goods to pasta to certain sauces and processed foods.

The demand for gluten-containing products remains strong in North America and Europe due to consumer preferences, culinary traditions, and the cultural significance of certain foods. It reflects the broader consumer preference for traditional, gluten-rich foods in the region which will further increases the risk of celiac disease. Thus rising demand for gluten-containing products is expected to act as driver for the North America and Europe celiac disease market.

Restraint

  • Complexity Of Celiac Disease

Celiac disease is a complex autoimmune disorder characterized by an abnormal immune response to gluten, a protein found in wheat, barley, rye, and their derivatives. The complexity of celiac disease arises from the intricate interplay of genetic, immunological, environmental, and dietary factors.

These complications make celiac disease a multifaceted and challenging autoimmune disorder to understand, diagnose, and manage. Thus complexity of celiac disease is expected to act as restraint for the North America and Europe celiac disease market.

Marché de la maladie cœliaque en Amérique du Nord et en Europe

Opportunity

  • Emerging Biological Therapies For Celiac Disease

Emerging biological therapies for celiac disease represent a promising avenue for developing alternative treatments beyond the current standard of care, which is a lifelong strict gluten-free diet. While these therapies are still in the experimental stages and undergoing clinical trials, they hold the potential to address the complexity associated with celiac disease, offering new possibilities for individuals affected by this autoimmune disorder. 

The development of biological therapies for celiac disease reflects a growing understanding of the underlying immunological mechanisms and a commitment to finding innovative solutions to improve the quality of life for individuals with this autoimmune disorder. As research progresses, these therapies may offer new options for the management of celiac disease beyond the limitations of a strict gluten-free diet. Thus emerging biological therapies for celiac disease is expected to act as opportunity for the North America and Europe celiac disease market.

Challenge

  • Patient Adherence To Gluten-Free Diet

While patient adherence to a gluten-free diet is crucial for managing celiac disease, it presents challenges for the celiac disease market. The celiac disease market faces challenges because a strict gluten-free diet is currently the only effective treatment. With limited pharmaceutical interventions or alternative therapies available, the market heavily relies on patients adhering to dietary restrictions. This lack of treatment diversity limits revenue streams for pharmaceutical companies operating in the celiac disease space.

Patient adherence to a gluten-free diet poses challenges for the celiac disease market, particularly in terms of limited treatment options, economic considerations, and the impact on pharmaceutical development. Thus patient adherence to gluten-free diet is expected to act as challenge for the North America and Europe celiac disease market.

Recent Developments

  • In October 2022, Takeda Pharmaceutical Company Limited, Zedira and Dr. Falk Pharma GmbH announced a collaboration and license agreement to develop ZED1227/TAK-227, a Phase 2b investigational drug in celiac disease. This collaboration will help the company to come up with the treatment of celiac disease
  • In June 2020, Janssen Pharmaceuticals, Inc. announced collaboration with Monash University and signed a multi-year research to advance the understanding of the immune mechanisms underpinning Coeliac Disease and inform the development of new methods of diagnosis and treatment. The collaboration brings together leading researchers and industry partners to tackle this major health issue to develop innovative immunotherapeutics to prevent and treat celiac isease

North America and Europe Celiac Disease Market Scope

North America and Europe celiac disease market is categorized into nine notable segments based on treatment type, diagnosis, disease type, drug type, prescription type, dosage form, route of administration, population type, end user and distribution channel.The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Treatment Type

  • Corticosteriods
  • Immunosuppressants
  • Others

On the basis of treatment type, the market is segmented into corticosteroids, immunosuppressants, and others.

Disease Type

  • Refractory Celiac Disease
  • Dermatitis Herpetiformis
  • Potential Celiac Disease
  • Classical Celiac Disease
  • Non-Classical Celiac Disease

On the basis of disease type, the market is segmented into refractory celiac disease, dermatitis herpetiformis, potential celiac disease, classical celiac disease, and non-classical celiac disease.

Drug Type

  • Generics
  • Branded

On the basis of drug type, the market is segmented into branded and generics.

Prescription Type

  • Prescription
  • Over The Counter

On the basis of prescription type, the market is segmented into prescription and over the counter.

Dosage Form

  • Tablet
  • Capsules
  • Injections
  • Other

On the basis of dosage form, the market is segmented into tablet, capsules, injections, and others.

Route of Administration

  • Oral
  • Intravenous
  • Topical

On the basis of route of administration, the market is segmented into oral, intravenous, and topical.

Population Type

  • Adults
  • Children
  • Geriatric

On the basis of population type, the market is segmented into adults, children, and geriatric.

End-User

  • Hospitals
  • Clinics
  • Home Care Settings
  • Others

On the basis of end user, the market is segmented into hospitals, clinics, home care settings, and others.

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.

Marché de la maladie cœliaque en Amérique du Nord et en Europe

North America and Europe Celiac Disease Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, treatment type, diagnosis, disease type, drug type, prescription type, dosage form, route of administration, population type, end user and distribution channel as referenced above.

The countries covered in this market report U.S., Canada, Mexico, Germany, France, Italy, Spain, U.K., Switzerland, Netherlands, Russia, Turkey, Poland, Sweden, Belgium, Denmark, Finland, Norway and Rest of Europe.

The U.S. region is expected to dominate the market due to the strong presence of market players in the region. The Germany region is expected to dominate the market due to high prevalence of celiac disease and advanced healthcare infrastructure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America and Europe Celiac Disease Market Share Analysis

North America and Europe celiac disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, product type lifeline curve. The above data points provided are only related to the company’s focus on the North America and Europe celiac disease market.

Certains des principaux acteurs opérant sur le marché de la maladie cœliaque en Amérique du Nord et en Europe sont Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals (filiale de Bausch Health Companies Inc.), Tillotts Pharma AG, GSK plc., ImmunogenX, Inc., Janssen Pharmaceuticals, Inc. (filiale de Johnson & Johnson Services, Inc.), Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., AstraZeneca, Novartis AG, AdvaCare Pharma, ANOKION, Topas Therapeutics, Immunic Therapeutics et Equillium Bio. entre autres.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TREATMENT TYPE LIFELINE CURVE FOR THE NORTH AMERICA CELIAC DISEASE MARKET

2.8 TREATMENT TYPE LIFELINE CURVE THE EUROPE CELIAC DISEASE MARKET

2.9 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.1 DBMR MARKET POSITION GRID

2.11 MARKET END USER COVERAGE GRID

2.12 VENDOR SHARE ANALYSIS

2.13 SECONDARY SOURCES

2.14 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSIS

4.2 PORTERS 5 FORCES

4.3 EPIDEMIOLOGY

5 PIPELINE ANALYSIS

6 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, REGULATORY FRAMEWORK

6.1 REGULATIONS IN NORTH AMERICA

6.1.1 U.S.

6.1.2 CANADA

6.2 REGULATIONS IN EUROPE

6.2.1 EUROPEAN UNION (EU)

6.2.2 U.K.

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE OF CELIAC DISEASE

7.1.2 RISING CONSUMPTION OF GLUTEN-CONTAINING PRODUCTS

7.1.3 INCREASING RESEARCH AND DEVELOPMENT FOR CELIAC DISEASE TREATMENTS

7.1.4 GROWING AWARENESS ABOUT CELIAC DISEASE

7.2 RESTRAINTS

7.2.1 COMPLEXITY OF CELIAC DISEASE

7.2.2 LIMITED TREATMENT OPTIONS FOR CELIAC DISEASE

7.3 OPPORTUNITIES

7.3.1 EMERGING BIOLOGICAL THERAPIES FOR CELIAC DISEASE

7.3.2 RISING ADVANCEMENTS IN DIAGNOSTIC APPROACHES OF CELIAC DISEASE

7.3.3 STRATEGIC COLLABORATION FOR COMMERCIALIZATION OF NOVEL THERAPIES FOR CELIAC DISEASE

7.4 CHALLENGES

7.4.1 PATIENT ADHERENCE TO GLUTEN-FREE DIET

7.4.2 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS USED FOR CELIAC DISEASE TREATMENT

8 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY TREATMENT TYPE

8.1 OVERVIEW

8.2 CORTICOSTERIODS

8.2.1 PREDNISONE

8.2.2 .BUDESONIDE

8.2.3 BETAMETHASONE

8.2.4 CLOBETASONE BUTYRATE

8.2.5 OTHERS

8.3 IMMUNOSUPPRESSANTS

8.3.1 AZATHIOPRINE

8.3.2 INFLIXIMAB

8.3.3 CYCLOSPORINE

8.3.4 CLADRIBINE

8.3.5 OTHERS

8.4 OTHERS

9 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DISEASE TYPE

9.1 OVERVIEW

9.2 REFRACTORY CELIAC DISEASE

9.2.1 TYPE I

9.2.2 TYPE II

9.3 DERMATITIS HERPETIFORMIS

9.4 POTENTIAL CELIAC DISEASE

9.5 CLASSICAL CELIAC DISEASE

9.6 NON-CLASSICAL CELIAC DISEASE

10 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DRUG TYPE

10.1 OVERVIEW

10.2 GENERICS

10.3 BRANDED

11 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE

11.1 OVERVIEW

11.2 PRESCRIPTION

11.3 OVER THE COUNTER

12 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DOSAGE FORM

12.1 OVERVIEW

12.2 TABLET

12.3 CAPSULES

12.4 INJECTIONS

12.5 OTHER

13 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 ORAL

13.2.1 TABLET

13.2.2 CAPSULES

13.2.3 OTHERS

13.3 INTRAVENOUS

13.4 TOPICAL

14 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY POPULATION TYPE

14.1 OVERVIEW

14.2 ADULTS

14.2.1 FEMALE

14.2.2 MALE

14.3 CHILDREN

14.4 GERIATRIC

14.4.1 FEMALE

14.4.2 MALE

15 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITALS

15.3 CLINICS

15.4 HOME CARE SETTINGS

15.5 OTHERS

16 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 HOSPITAL PHARMACY

16.3 RETAIL PHARMACY

16.4 ONLINE PHARMACY

16.5 OTHERS

17 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY GEOGRAPHY

17.1 NORTH AMERICA

17.1.1 U.S.

17.1.2 CANADA

17.1.3 MEXICO

17.2 EUROPE

17.2.1 GERMANY

17.2.2 FRANCE

17.2.3 ITALY

17.2.4 SPAIN

17.2.5 U.K.

17.2.6 SWITZERLAND

17.2.7 NETHERLANDS

17.2.8 RUSSIA

17.2.9 TURKEY

17.2.10 POLAND

17.2.11 SWEDEN

17.2.12 BELGIUM

17.2.13 DENMARK

17.2.14 FINLAND

17.2.15 NORWAY

17.2.16 REST OF EUROPE

18 NORTH AMERICA CELIAC DISEASE MARKET: COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

19 EUROPE CELIAC DISEASE MARKET: COMPANY LANDSCAPE

19.1 COMPANY SHARE ANALYSIS: EUROPE

20 SWOT ANALYSIS

21 COMPANY PROFILES

21.1 GSK PLC.

21.1.1 COMPANY SNAPSHOT

21.1.2 REVENUE ANALYSIS

21.1.3 PRODUCT PORTFOLIO

21.1.4 RECENT DEVELOPMENT

21.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

21.2.1 COMPANY SNAPSHOT

21.2.2 REVENUE ANALYSIS

21.2.3 PRODUCT PORTFOLIO

21.2.4 RECENT DEVELOPMENT

21.3 PFIZER INC.

21.3.1 COMPANY SNAPSHOT

21.3.2 REVENUE ANALYSIS

21.3.3 PRODUCT PORTFOLIO

21.3.4 RECENT DEVELOPMENT

21.4 TEVA PHARMACEUTICALS USA, INC.

21.4.1 COMPANY SNAPSHOT

21.4.2 REVENUE ANALYSIS

21.4.3 PRODUCT PORTFOLIO

21.4.4 RECENT DEVELOPMENT

21.5 NOVARTIS AG

21.5.1 COMPANY SNAPSHOT

21.5.2 REVENUE ANALYSIS

21.5.3 PRODUCT PORTFOLIO

21.5.4 RECENT DEVELOPMENT

21.6 ADVACARE PHARMA

21.6.1 COMPANY SNAPSHOT

21.6.2 PRODUCT PORTFOLIO

21.6.3 RECENT DEVELOPMENT

21.7 AMGEN INC.

21.7.1 COMPANY SNAPSHOT

21.7.2 REVENUE ANALYSIS

21.7.3 PRODUCT PORTFOLIO

21.7.4 RECENT DEVELOPMENT

21.8 ANOKION

21.8.1 COMPANY SNAPSHOT

21.8.2 PRODUCT PORTFOLIO

21.8.3 RECENT DEVELOPMENT

21.9 EQUILLIUM BIO.

21.9.1 COMPANY SNAPSHOT

21.9.2 PRODUCT PORTFOLIO

21.9.3 RECENT DEVELOPMENT

21.1 IMMUNIC THERAPEUTICS

21.10.1 COMPANY SNAPSHOT

21.10.2 PRODUCT PORTFOLIO

21.10.3 RECENT DEVELOPMENT

21.11 IMMUNOGENX, INC.

21.11.1 COMPANY SNAPSHOT

21.11.2 PRODUCT PORTFOLIO

21.11.3 RECENT DEVELOPMENT

21.12 SALIX PHARMACEUTICALS (SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)

21.12.1 COMPANY SNAPSHOT

21.12.2 REVENUE ANALYSIS OF PARENT COMPANY

21.12.3 PRODUCT PORTFOLIO

21.12.4 RECENT DEVELOPMENT

21.13 TAKEDA PHARMACEUTICAL COMPANY LIMITED

21.13.1 COMPANY SNAPSHOT

21.13.2 REVENUE ANALYSIS

21.13.3 PRODUCT PORTFOLIO

21.13.4 RECENT DEVELOPMENT

21.14 TILLOTTS PHARMA AG

21.14.1 COMPANY SNAPSHOT

21.14.2 PRODUCT PORTFOLIO

21.14.3 RECENT DEVELOPMENT

21.15 TOPAS THERAPEUTICS

21.15.1 COMPANY SNAPSHOT

21.15.2 PRODUCT PORTFOLIO

21.15.3 RECENT DEVELOPMENT

22 QUESTIONNAIRE

23 RELATED REPORTS

Liste des tableaux

TABLE 1 PIPELINE ANALYSIS FOR NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET

TABLE 2 NORTH AMERICA CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 3 EUROPE CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 4 NORTH AMERICA CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 5 NORTH AMERICA CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 6 EUROPE CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 7 EUROPE CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 8 NORTH AMERICA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 9 NORTH AMERICA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 10 EUROPE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 11 EUROPE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 12 NORTH AMERICA CELIAC DISEASE MARKET, BY DISEASE TYPE, 2022-2031 (USD THOUSAND)

TABLE 13 EUROPE CELIAC DISEASE MARKET, BY DISEASE TYPE, 2022-2031 (USD THOUSAND)

TABLE 14 NORTH AMERICA REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 15 EUROPE REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 16 NORTH AMERICA CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 17 EUROPE CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 18 NORTH AMERICA CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 19 EUROPE CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 20 NORTH AMERICA CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 21 EUROPE CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 22 NORTH AMERICA CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 23 EUROPE CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 24 NORTH AMERICA CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 25 EUROPE CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 26 NORTH AMERICA CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 27 EUROPE CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 28 NORTH AMERICA ADULTS IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 29 EUROPE ADULTS IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 30 NORTH AMERICA GERIATRIC IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 31 EUROPE GERAITRIC IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 32 NORTH AMERICA CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 33 EUROPE CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 34 NORTH AMERICA CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 35 EUROPE CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 36 NORTH AMERICA CELIAC DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 37 U.S. CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 38 U.S. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 39 U.S. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 40 U.S. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 41 U.S. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 42 U.S. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 43 U.S. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 44 U.S. CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 45 U.S. REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 46 U.S. CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 47 U.S. CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 48 U.S. CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 49 U.S. CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 50 U.S. ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 51 U.S. CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 52 U.S. ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 53 U.S. GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 54 U.S. CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 55 U.S. CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 56 CANADA CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 57 CANADA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 58 CANADA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 59 CANADA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 60 CANADA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 61 CANADA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 62 CANADA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 63 CANADA CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 64 CANADA REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 65 CANADA CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 66 CANADA CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 67 CANADA CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 68 CANADA CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 69 CANADA ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 70 CANADA CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 71 CANADA ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 72 CANADA GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 73 CANADA CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 74 CANADA CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 75 MEXICO CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 76 MEXICO CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 77 MEXICO CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 78 MEXICO CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 79 MEXICO IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 80 MEXICO IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 81 MEXICO IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 82 MEXICO CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 83 MEXICO REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 84 MEXICO CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 85 MEXICO CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 86 MEXICO CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 87 MEXICO CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 88 MEXICO ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 89 MEXICO CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 90 MEXICO ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 91 MEXICO GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 92 MEXICO CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 93 MEXICO CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 94 EUROPE CELIAC DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 95 GERMANY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 96 GERMANY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 97 GERMANY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 98 GERMANY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 99 GERMANY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 100 GERMANY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 101 GERMANY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 102 GERMANY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 103 GERMANY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 104 GERMANY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 105 GERMANY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 106 GERMANY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 107 GERMANY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 108 GERMANY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 109 GERMANY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 110 GERMANY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 111 GERMANY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 112 GERMANY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 113 GERMANY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 114 FRANCE CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 115 FRANCE CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 116 FRANCE CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 117 FRANCE CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 118 FRANCE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 119 FRANCE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 120 FRANCE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 121 FRANCE CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 122 FRANCE REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 123 FRANCE CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 124 FRANCE CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 125 FRANCE CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 126 FRANCE CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 127 FRANCE ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 128 FRANCE CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 129 FRANCE ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 130 FRANCE GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 131 FRANCE CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 132 FRANCE CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 133 ITALY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 134 ITALY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 135 ITALY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 136 ITALY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 137 ITALY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 138 ITALY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 139 ITALY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 140 ITALY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 141 ITALY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 142 ITALY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 143 ITALY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 144 ITALY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 145 ITALY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 146 ITALY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 147 ITALY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 148 ITALY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 149 ITALY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 150 ITALY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 151 ITALY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 152 SPAIN CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 153 SPAIN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 154 SPAIN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 155 SPAIN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 156 SPAIN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 157 SPAIN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 158 SPAIN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 159 SPAIN CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 160 SPAIN REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 161 SPAIN CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 162 SPAIN CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 163 SPAIN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 164 SPAIN CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 165 SPAIN ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 166 SPAIN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 167 SPAIN ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 168 SPAIN GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 169 SPAIN CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 170 SPAIN CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 171 U.K. CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 172 U.K. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 173 U.K. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 174 U.K. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 175 U.K. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 176 U.K. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 177 U.K. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 178 U.K. CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 179 U.K. REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 180 U.K. CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 181 U.K. CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 182 U.K. CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 183 U.K. CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 184 U.K. ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 185 U.K. CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 186 U.K. ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 187 U.K. GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 188 U.K. CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 189 U.K. CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 190 SWITZERLAND CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 191 SWITZERLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 192 SWITZERLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 193 SWITZERLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 194 SWITZERLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 195 SWITZERLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 196 SWITZERLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 197 SWITZERLAND CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 198 SWITZERLAND REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 199 SWITZERLAND CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 200 SWITZERLAND CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 201 SWITZERLAND CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 202 SWITZERLAND CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 203 SWITZERLAND ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 204 SWITZERLAND CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 205 SWITZERLAND ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 206 SWITZERLAND GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 207 SWITZERLAND CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 208 SWITZERLAND CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 209 NETHERLANDS CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 210 NETHERLANDS CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 211 NETHERLANDS CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 212 NETHERLANDS CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 213 NETHERLANDS IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 214 NETHERLANDS IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 215 NETHERLANDS IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 216 NETHERLANDS CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 217 NETHERLANDS REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 218 NETHERLANDS CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 219 NETHERLANDS CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 220 NETHERLANDS CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 221 NETHERLANDS CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 222 NETHERLANDS ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 223 NETHERLANDS CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 224 NETHERLANDS ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 225 NETHERLANDS GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 226 NETHERLANDS CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 227 NETHERLANDS CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 228 RUSSIA CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 229 RUSSIA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 230 RUSSIA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 231 RUSSIA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 232 RUSSIA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 233 RUSSIA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 234 RUSSIA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 235 RUSSIA CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 236 RUSSIA REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 237 RUSSIA CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 238 RUSSIA CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 239 RUSSIA CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 240 RUSSIA CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 241 RUSSIA ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 242 RUSSIA CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 243 RUSSIA ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 244 RUSSIA GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 245 RUSSIA CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 246 RUSSIA CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 247 TURKEY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 248 TURKEY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 249 TURKEY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 250 TURKEY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 251 TURKEY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 252 TURKEY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 253 TURKEY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 254 TURKEY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 255 TURKEY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 256 TURKEY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 257 TURKEY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 258 TURKEY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 259 TURKEY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 260 TURKEY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 261 TURKEY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 262 TURKEY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 263 TURKEY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 264 TURKEY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 265 TURKEY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 266 POLAND CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 267 POLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 268 POLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 269 POLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 270 POLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 271 POLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 272 POLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 273 POLAND CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 274 POLAND REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 275 POLAND CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 276 POLAND CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 277 POLAND CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 278 POLAND CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 279 POLAND ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 280 POLAND CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 281 POLAND ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 282 POLAND GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 283 POLAND CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 284 POLAND CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 285 SWEDEN CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 286 SWEDEN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 287 SWEDEN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 288 SWEDEN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 289 SWEDEN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 290 SWEDEN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 291 SWEDEN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 292 SWEDEN CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 293 SWEDEN REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 294 SWEDEN CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 295 SWEDEN CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 296 SWEDEN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 297 SWEDEN CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 298 SWEDEN ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 299 SWEDEN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 300 SWEDEN ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 301 SWEDEN GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 302 SWEDEN CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 303 SWEDEN CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 304 BELGIUM CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 305 BELGIUM CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 306 BELGIUM CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 307 BELGIUM CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 308 BELGIUM IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 309 BELGIUM IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 310 BELGIUM IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 311 BELGIUM CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 312 BELGIUM REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 313 BELGIUM CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 314 BELGIUM CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 315 BELGIUM CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 316 BELGIUM CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 317 BELGIUM ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 318 BELGIUM CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 319 BELGIUM ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 320 BELGIUM GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 321 BELGIUM CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 322 BELGIUM CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 323 DENMARK CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 324 DENMARK CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 325 DENMARK CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 326 DENMARK CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 327 DENMARK IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 328 DENMARK IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 329 DENMARK IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 330 DENMARK CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 331 DENMARK REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 332 DENMARK CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 333 DENMARK CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 334 DENMARK CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 335 DENMARK CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 336 DENMARK ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 337 DENMARK CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 338 DENMARK ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 339 DENMARK GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 340 DENMARK CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 341 DENMARK CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 342 FINLAND CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 343 FINLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 344 FINLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 345 FINLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 346 FINLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 347 FINLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 348 FINLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 349 FINLAND CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 350 FINLAND REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 351 FINLAND CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 352 FINLAND CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 353 FINLAND CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 354 FINLAND CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 355 FINLAND ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 356 FINLAND CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 357 FINLAND ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 358 FINLAND GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 359 FINLAND CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 360 FINLAND CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 361 NORWAY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 362 NORWAY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 363 NORWAY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 364 NORWAY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 365 NORWAY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 366 NORWAY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 367 NORWAY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 368 NORWAY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 369 NORWAY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 370 NORWAY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 371 NORWAY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 372 NORWAY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 373 NORWAY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 374 NORWAY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 375 NORWAY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 376 NORWAY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 377 NORWAY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 378 NORWAY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 379 NORWAY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 380 REST OF EUROPE CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

Liste des figures

FIGURE 1 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA CELIAC DISEASE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 EUROPE CELIAC DISEASE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 6 NORTH AMERICA CELIAC DISEASE MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 7 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA CELIAC DISEASE MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE CELIAC DISEASE MARKET: DBMR MARKET POSITION GRID

FIGURE 10 NORTH AMERICA CELIAC DISEASE MARKET: MARKET END USER COVERAGE GRID

FIGURE 11 EUROPE CELIAC DISEASE MARKET: MARKET END USER COVERAGE GRID

FIGURE 12 NORTH AMERICA CELIAC DISEASE MARKET: VENDOR SHARE ANALYSIS

FIGURE 13 EUROPE CELIAC DISEASE MARKET: VENDOR SHARE ANALYSIS

FIGURE 14 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: SEGMENTATION

FIGURE 15 THE INCREASING PREVALENCE OF CELIAC DISEASE IS DRIVING THE GROWTH OF THE NORTH AMERICA CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 16 RISING CONSUMPTION OF GLUTEN-CONTAINING PRODUCTS IS DRIVING THE GROWTH OF THE EUROPE CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 17 CORTICOSTEROIDS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 AND 2031

FIGURE 18 CARTICOSTEROIDS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 AND 2031

FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET

FIGURE 20 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2023

FIGURE 21 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2024-2031 (USD THOUSAND)

FIGURE 22 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, CAGR (2024-2031)

FIGURE 23 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 24 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2023

FIGURE 25 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2024-2031 (USD THOUSAND)

FIGURE 26 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, CAGR (2024-2031)

FIGURE 27 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 28 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, 2023

FIGURE 29 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, 2024-2031 (USD THOUSAND)

FIGURE 30 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, CAGR (2024-2031)

FIGURE 31 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 32 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, 2023

FIGURE 33 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, 2024-2031 (USD THOUSAND)

FIGURE 34 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, CAGR (2024-2031)

FIGURE 35 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 36 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, 2023

FIGURE 37 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)

FIGURE 38 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, CAGR (2024-2031)

FIGURE 39 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 40 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, 2023

FIGURE 41 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)

FIGURE 42 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, CAGR (2024-2031)

FIGURE 43 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 44 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2023

FIGURE 45 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2024-2031 (USD THOUSAND)

FIGURE 46 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, CAGR (2024-2031)

FIGURE 47 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, LIFELINE CURVE

FIGURE 48 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2023

FIGURE 49 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2024-2031 (USD THOUSAND)

FIGURE 50 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, CAGR (2024-2031)

FIGURE 51 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, LIFELINE CURVE

FIGURE 52 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, 2023

FIGURE 53 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND)

FIGURE 54 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, CAGR (2024-2031)

FIGURE 55 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 56 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, 2023

FIGURE 57 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND)

FIGURE 58 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, CAGR (2024-2031)

FIGURE 59 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 60 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2023

FIGURE 61 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)

FIGURE 62 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)

FIGURE 63 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 64 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2023

FIGURE 65 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)

FIGURE 66 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)

FIGURE 67 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 68 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, 2023

FIGURE 69 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, 2024-2031 (USD THOUSAND)

FIGURE 70 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, CAGR (2024-2031)

FIGURE 71 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 72 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, 2023

FIGURE 73 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, 2024-2031 (USD THOUSAND)

FIGURE 74 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, CAGR (2024-2031)

FIGURE 75 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 76 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, 2023

FIGURE 77 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, 2024-2031 (USD THOUSAND)

FIGURE 78 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, CAGR (2024-2031)

FIGURE 79 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, LIFELINE CURVE

FIGURE 80 EUROPE CELIAC DISEASE MARKET: BY END USER, 2023

FIGURE 81 EUROPE CELIAC DISEASE MARKET: BY END USER, 2024-2031 (USD THOUSAND)

FIGURE 82 EUROPE CELIAC DISEASE MARKET: BY END USER, CAGR (2024-2031)

FIGURE 83 EUROPE CELIAC DISEASE MARKET: BY END USER, LIFELINE CURVE

FIGURE 84 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 85 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)

FIGURE 86 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 87 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 88 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 89 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)

FIGURE 90 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 91 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 92 NORTH AMERICA CELIAC DISEASE MARKET: SNAPSHOT (2023)

FIGURE 93 EUROPE CELIAC DISEASE MARKET: SNAPSHOT (2023)

FIGURE 94 NORTH AMERICA CELIAC DISEASE MARKET: COMPANY SHARE 2023 (%)

FIGURE 95 EUROPE CELIAC DISEASE MARKET: COMPANY SHARE 2023 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

The North America and Europe Celiac Disease Market size will be worth USD 150,949.09 thousand during the forecast period by 2031.
The North America and Europe Celiac Disease Market growth rate is 8.8% during the forecast period.
Increasing Prevalence Of Celiac Disease & Rising Demand For Gluten Containing Products are the growth drivers of the North America and Europe Celiac Disease Market.
The treatment type, diagnosis, disease type, drug type, prescription type, dosage form, route of administration, population type, end user and distribution channel are the factors on which the North America and Europe Celiac Disease Market research is based.
Major companies in the North America and Europe Celiac Disease Market are Tillotts Pharma AG, GSK plc., ImmunogenX, Inc., Janssen Pharmaceuticals, Inc. (subsidiary of Johnson & Johnson Services, Inc.), Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., AstraZeneca, Novartis AG, AdvaCare Pharma, ANOKION, Topas Therapeutics, Immunic Therapeutics and Equillium Bio.